Latest News

The listing below shows our latest News Items and is updated regularly.  If you wish to post a news item please select the 'Post News' button on the right.  The displayed news feed starts on 1st August 2016.  Older items can be found here.

To 'Post Your News' use the button at the top right.



From the monthly archives: December, 2017

We are pleased to present below all posts archived in 'December, 2017'. If you still can't find what you are looking for, try using the search box.

Boehringer Ingelheim signs Evox, Roche deals

A second deal between Germany’s Boehringer Ingelheim and a UK firm has been announced this week, this time with Oxford-based Evox Therapeutics for a collaboration focused on exosome-mediated drug delivery.

Read the rest of entry »

Isansys Lifecare partners with myHealth Sentinel

Isansys Lifecare, a global health technology company, is delighted to announce its partnership with myHealth Sentinel (mHS) to offer its wireless, wearable, continuous patient data capture and analysis platform in Singapore.

Read the rest of entry »

Isansys Lifecare partners with myHealth Sentinel

Oxford, UK: Isansys Lifecare, a global health technology company, is delighted to announce its partnership with myHealth Sentinel (mHS) to offer its wireless, wearable, continuous patient data capture and analysis platform in Singapore.

Read the rest of entry »

Corporate venture investment in UK biotech increases more than 6-fold in 5 years

New research published 14 December by the Association of the British Pharmaceutical Industry (ABPI) shows that the amount of capital invested alongside CVC into UK companies increased six-fold between 2010 and 2015, marking a fundamental shift in how start-up British biotech is funded. 

Read the rest of entry »

Highly Efficient Substrate for Culturing ES/iPS Cells

AMSBIO announces iMatrix recombinant Laminin-511 E8 fragments, an innovative cell culture matrix compatible with a wide variety of cell types, and exceptionally well suited for pluripotent stem cells.

Read the rest of entry »

Oxford Immunotec and QIAGEN N.V. Settle Patent Infringement Lawsuit

Oxford Immunotec Ltd. and QIAGEN N.V. announced today that they have reached a settlement in the lawsuit in the U.S. District Court for the District of Massachusetts in Boston (15-cv-13124-NMG) alleging patent infringement in relation to QIAGEN’s QuantiFERON®-TB Gold and QuantiFERON®-TB Gold Plus products.

Read the rest of entry »

Sanifit appoints Alexander M. Gold, M.D., F.A.C.C. as Chief Medical Officer and President of its US subsidiary

Former SVP and Head of Clinical Development at Portola Pharmaceuticals appointed as Chief Medical Officer

Read the rest of entry »

PsiOxus Therapeutics Receives $15 Million Milestone Payment as Armed Oncolytic Virus Licensed to Bristol-Myers Squibb Achieves CTA

PsiOxus Therapeutics, Ltd. (PsiOxus) today announced that the Clinical Trial Application for NG-348, an “armed” oncolytic virus for the treatment of solid tumors, has been approved and, per the licensing agreement between the parties, Bristol-Myers Squibb will make a US $15 million milestone payment to PsiOxus.

Read the rest of entry »

Exscientia Appoints Alex Snow, Founder of Oxford Innovation Sciences and Former CEO of Lansdowne Partners, as Deputy Chairman

Exscientia, the innovative company at the forefront of Artificial Intelligence (AI)-driven drug discovery, is pleased to announce the appointment of Mr Alex Snow to its Board of Directors as Deputy Chairman. He brings significant strategic development and financial experience to the board.

Read the rest of entry »

Immunocore’s IMCgp100 Receives Promising Innovative Medicine (PIM) Designation Under UK Early Access to Medicines Scheme (EAMS) for the Treatment of Patients with Uveal Melanoma

Immunocore Limited, the world’s leading TCR company focused on delivering first-in-class biological therapies that transform lives, today announces that it has been informed by the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) that IMCgp100 has been granted Promising Innovative Medicines (PIM) designation for the treatment of patients with metastatic uveal melanoma.

Read the rest of entry »

Pages: Previous12NextReturn Top

Search Posts

News Policy

OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.